” This year we continue the important work of laying the foundation for Sangamo as a sustainable, fully integrated company that develops, manufacturers and commercializes novel genomic therapies on our own and, where appropriate, in collaboration with industry partners. “

-Sandy Macrae, CEO of Sangamo.

 

[Image source: Businesswire.com]

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a clinical stage biopharmaceutical company that focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

After I Know First released its forecast on April 4, 2018, Sangamo stock price jumped from $4.20 to $19.45 per share, outperforming the market by some 280%. The reason for the outstanding growth is reflected in the company’s results for 2017 released on February 22, 2018 with the following highlights:

• Net loss was $54.6 million, or $0.70 per share, compared to $71.7 million, or $1.02 per share, for 2016
• Revenues for 2017 were $36.6 million compared to $19.4 million for 2016
• Total operating expenses for 2017 were $92.9 compared to $91.9 million for 2016

From the above figures one can see that the company’s losses decreased in 2017 comparing to 2016, and the revenues almost doubled. However, the total operating expenses of the company for 2017 also increased.  This shows that the company succeeded to improve revenue generation while keeping the overall costs structure stable, thus bringing more value to the investors.

 

[Image Source: Yahoo Finance]

Finally, the latest Yahoo Finance data supports the positive outlook and shows that 5 of 6 analyst covering the company’s activity propose buy positions. The stock price growth from April 4, 2017 to April 4, 2018 with regards Sangamo Therapeutics’ stock is presented below:

 

[Image Source: Yahoo Finance]

On April 4, 2018 I Know First released a 1 year forecast for Sangamo Therapeutics (NASDAQ: SGMO). The forecast showed a signal of 129.33 and a predictability of 0.57 In accordance with the forecast. SGMO’s stock returned 278% after 1 year, highlighting the accuracy of the prediction produced by the I Know First algorithm.

Current I Know First subscribers received this bullish SGMO forecast on April 4, 2018  

To subscribe today click here.

 

How to read the I Know First Forecast

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.